XM does not provide services to residents of the United States of America.
F
F

Fresenius

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Fresenius And Formycon Reach Settlement With Johnson & Johnson For Ustekinumab Candidate

BRIEF-Fresenius And Formycon Reach Settlement With Johnson & Johnson For Ustekinumab Candidate March 18 (Reuters) - Fresenius SE & Co KGaA FREG.DE : FRESENIUS KABI AND FORMYCON REACH AGREEMENT FOR USTEKINUMAB BIOSIMILAR CANDIDATE FRESENIUS KABI AND FORMYCON HAVE REACHED A SETTLEMENT WITH JOHNSON & JOHNSON FOR FYB202 THE TERMS OF THE SETTLEMENT ARE
F

Fresenius' Supervisory Board Extends Contract Of CFO Sara Hennicken Ahead Of Time

BRIEF-Fresenius' Supervisory Board Extends Contract Of CFO Sara Hennicken Ahead Of Time March 8 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : SUPERVISORY BOARD EXTENDS CONTRACT OF CHIEF FINANCIAL OFFICER SARA HENNICKEN AHEAD OF TIME EXTENDED SARA HENNICKEN'S MANDATE AS CHIEF FINANCIAL OFFICER (CFO) AHEAD OF TIME UNTIL 2027. Further company coverage:
F

Fresenius Supervisory Board Extends Contract Of CFO Sara Hennicken Until 2027

BRIEF-Fresenius Supervisory Board Extends Contract Of CFO Sara Hennicken Until 2027 March 8 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : FRESENIUS SUPERVISORY BOARD EXTENDS CONTRACT OF CHIEF FINANCIAL OFFICER SARA HENNICKEN AHEAD OF TIME EXTENDED HENNICKEN'S MANDATE UNTIL 2027 Further company coverage: FREG.DE (Gdansk Newsroom)
F

Fresenius Says Kabi's Biosimilar Tyenne Approved By FDA

BRIEF-Fresenius Says Kabi's Biosimilar Tyenne Approved By FDA March 7 (Reuters) - Fresenius SE & Co KGaA FREG.DE : FRESENIUS SE - FRESENIUS KABI'S BIOSIMILAR TYENNE® (TOCILIZUMAB-AAZG) BECOMES FIRST IV AND SUBCUTANEOUS TOCILIZUMAB BIOSIMILAR APPROVED BY FDA Source text for Eikon: [ID:] Further company coverage: FREG.DE (Gdansk Newsroom)
F

Edpr, ENI, Repsol

EUROPE RESEARCH ROUNDUP-Edpr, ENI, Repsol Feb 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Edpr, ENI and Repsol, on Thursday. HIGHLIGHTS * Digital Workforce Services Oyj DWFS.HE : Inderes cuts to reduce from accumulate * Edpr EDPR.LS : Exane BNP Paribas raises to outperform from neutral * ENI ENI.MI : Exane BNP Paribas cuts to underperform from neutral * Repsol REP.MC : Exane BNP Paribas raises to outperform from neutral * So
A
A
A
A
B
C
C
D
E
E
E
E
F
G
H
H
H
K
M
M
S
U
D
E

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.